A three-stage discounted cash flow valuation of a hypothetical consumer wellness brand, built to establish a defensible fair-value range ahead of a minority stake negotiation.
Modeled as an outside investor evaluating a minority stake in a growing D2C wellness brand with strong revenue growth but thin current profitability. The core question: what's a defensible valuation range to anchor a negotiation, given the company won't hit steady-state margins for several years?
| Revenue CAGR (yrs 1–5) | 24% |
| Revenue CAGR (yrs 6–10) | 11% |
| Terminal growth rate | 4.5% |
| WACC | 13.2% |
| Steady-state EBITDA margin | 18% |
| Forecast horizon | 10 years + terminal |
Built a three-stage model — high-growth, transition, and terminal — rather than a flat single-stage DCF, since early-stage consumer brands rarely grow at one constant rate. WACC was built up from a comparable-company beta, current risk-free rate, and an equity risk premium, then cross-checked against a comps-based valuation to sanity-check the DCF wasn't wildly out of line with how the market prices similar brands.
| 4.0% | 4.5% | 5.0% | |
|---|---|---|---|
| 12.2% | 920 | 980 | 1,050 |
| 13.2% | 840 | 895 | 960 |
| 14.2% | 770 | 815 | 870 |